Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
RESEARCH TOOLSreports
Holding BLCO?
Track your performance easily
BLCO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.16 - $18.58
Previous Close$18.56
Volume3.08M
Average Volume (3M)695.46K
Market Cap
$6.53B
Enterprise Value$10.95B
Total Cash (Recent Filing)$285.00M
Total Debt (Recent Filing)$4.63B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Oct 30, 2024EPS Estimate
$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding351,895,407
10 Day Avg. Volume920,736
30 Day Avg. Volume695,461
Standard Deviation0.09
R-Squared0.07
Alpha-0.00323
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)1.39
Price to Cash Flow (P/CF)91.20
P/FCF Ratio9.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit4.37
Enterprise Value/Ebitda13.62
Forecast
1Y Price Target
$18.61Price Target Upside-6.95% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bausch + Lomb Corporation News
Bulls Say, Bears Say
Bulls Say
Product PerformanceMiebo and Xiidra delivered $42M and $89M in revenue in 2Q24, respectively, demonstrating the company’s leading position in the space of dry eye disease therapeutics.
Revenue And EarningsManagement raised 2024 revenue guidance to $4.70-4.80B, corresponding to 16-18% constant currency revenue growth, with adjusted EBITDA of $850-900M, signaling strong future financial performance.
Sale ExplorationBLCO is exploring a sale as a way to separate from its parent company, BHC, likely drawing interest from private equity and resulting in a sizable premium to the current valuation due to its strong performance.
Bears Say
Financial PerformanceNet loss was $151M, or ($0.43) per share, higher than estimated loss of $81M, primarily due to an increase in interest expense and provision for taxes.
Market CompetitionMedical device peers ALC, COO, and JNJ would encounter anti-trust issues given each has anywhere from 25-40% of the contact lens market.
Stock ValuationBLCO shares are trading at a steep discount to its closest eye care peers.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $13.16 and its highest was $18.58 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Currently, no data Available
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 31, 2024. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.128 by $0.002.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Overvalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is $0.16.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 351,895,420 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.13 in its last earnings report, beating expectations of $0.128. Following the earnings report the stock price went up 2.075%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Among the largest hedge funds holding Bausch + Lomb Corporation’s share is Goldentree Asset Management Lp. It holds Bausch + Lomb Corporation’s shares valued at 74M.
---
Bausch + Lomb Corporation Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.61 (-6.95% Downside)
$18.61 (-6.95% Downside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $505.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.51%
12-Months-Change
Fundamentals
Return on Equity
-6.77%
Trailing 12-Months
Asset Growth
17.10%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
---
BLCO Company Deck
---
BLCO Earnings Call
Q2 2024
0:00 / 0:00
---
BLCO Stock 12 Month Forecast
Average Price Target
$18.61
▼(-6.95% Downside)
Technical Analysis
Best Analysts Covering BLCO
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+10.99%
reiterated a buy rating 6 days ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +10.99% per trade.
---